A <i>BAP1</i> Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type <i>BAP1</i>.

J Cancer · 2017 · PMC5595094 · PMID 28900502

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

showed a trendP =0.006actually significant

The ccRCC patients with mutated BAP1 showed a trend towards higher AJCC stage ( P =0.006), pathologic T stage ( P =0.009), Fuhrman grade ( P =0.003) and distant metastasis ( P =0.029) compared with those with wild-type BAP1 ( Table 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.